MitoxantroneVidarabineVidarabine PhosphateLeukemia, Lymphocytic, Chronic, B-CellAntineoplastic Combined Chemotherapy ProtocolsChlorambucilAntineoplastic AgentsCytarabineArabinonucleotidesCyclophosphamideTransplantation ConditioningAntibodies, Monoclonal, Murine-DerivedCladribineRemission InductionAnthraquinonesDrug Resistance, NeoplasmPrednisoneMyeloablative AgonistsLymphoma, Non-HodgkinIdarubicinTreatment OutcomeArabinofuranosylcytosine TriphosphateBusulfanLymphoma, FollicularLeukemia, Myeloid, AcuteDrug Administration ScheduleDoxorubicinATP-Binding Cassette TransportersHematopoietic Stem Cell TransplantationSurvival AnalysisDisease-Free SurvivalSalvage TherapyDrug Resistance, MultipleEtoposideWaldenstrom MacroglobulinemiaLeukemia, MyeloidTransplantation, HomologousAntimetabolites, AntineoplasticSurvival RateRecurrenceDrug EvaluationMelphalanGraft vs Host DiseaseTransplantation ChimeraArabinonucleosidesNeoplasm ProteinsInfusions, IntravenousAntibodies, NeoplasmDaunorubicinVincristineP-GlycoproteinMyelodysplastic SyndromesHematologic NeoplasmsAmsacrineEquilibrative-Nucleoside Transporter 2Antibodies, MonoclonalNeutropeniaRazoxaneTopoisomerase InhibitorsDrug Screening Assays, AntitumorInfectionIntercalating AgentsHematologic DiseasesTaxoidsAcute DiseaseDrug SynergismEstramustineWhole-Body IrradiationDose-Response Relationship, DrugImmunosuppressive AgentsTumor Cells, CulturedTopotecanCombined Modality TherapyCardiotoxinsNeoplasms, Second PrimaryLymphoma, Mantle-CellPrednisoloneProstatic NeoplasmsThrombocytopeniaGraft vs Tumor EffectLeukemiaGranulocyte Colony-Stimulating FactorDNA Topoisomerases, Type IIAntilymphocyte SerumCell Survival